Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Extension Study of Pegcetacoplan in Geographic Atrophy Secondary to AMD
2020-002931-32Phase 3Active
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jun 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in age-related macular degeneration (AMD), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and severity of ocular and systemic adverse events. Started Jun 2021; status: active.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2020-002931-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002931-32.